Crossmark Global Holdings Inc. lessened its position in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 1.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,130 shares of the company’s stock after selling 130 shares during the period. Crossmark Global Holdings Inc.’s holdings in Medpace were worth $683,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of MEDP. Marshall Wace LLP bought a new stake in shares of Medpace during the 1st quarter worth approximately $99,000. Marshall Wace North America L.P. lifted its holdings in shares of Medpace by 643.4% during the 1st quarter. Marshall Wace North America L.P. now owns 5,449 shares of the company’s stock worth $321,000 after acquiring an additional 4,716 shares during the period. FMR LLC lifted its holdings in shares of Medpace by 6,709.3% during the 1st quarter. FMR LLC now owns 37,247 shares of the company’s stock worth $2,196,000 after acquiring an additional 36,700 shares during the period. WINTON GROUP Ltd lifted its holdings in shares of Medpace by 105.6% during the 2nd quarter. WINTON GROUP Ltd now owns 11,876 shares of the company’s stock worth $777,000 after acquiring an additional 6,101 shares during the period. Finally, Scout Investments Inc. lifted its holdings in shares of Medpace by 75.2% during the 2nd quarter. Scout Investments Inc. now owns 106,217 shares of the company’s stock worth $6,949,000 after acquiring an additional 45,592 shares during the period. 83.45% of the stock is owned by institutional investors.
Shares of NASDAQ MEDP opened at $80.32 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.66 and a current ratio of 0.66. Medpace Holdings Inc has a 52-week low of $45.88 and a 52-week high of $86.71. The firm has a 50 day moving average price of $82.05 and a two-hundred day moving average price of $67.44. The stock has a market cap of $2.83 billion, a P/E ratio of 27.34, a price-to-earnings-growth ratio of 2.16 and a beta of 1.55.
MEDP has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday. SunTrust Banks upped their price target on shares of Medpace to $85.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. BidaskClub downgraded shares of Medpace from a “strong-buy” rating to a “buy” rating in a report on Friday, October 4th. ValuEngine downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Credit Suisse Group increased their price objective on shares of Medpace from $65.00 to $77.00 and gave the company an “outperform” rating in a research note on Tuesday, July 30th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Medpace currently has an average rating of “Buy” and an average target price of $78.00.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: Ex-Dividend
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.